Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Using real-world data (RWD) from three U.S. claims data sets, we aim to predict the findings of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) comparing linagliptin versus glimepiride in patients with type 2 diabetes (T2D) at increased cardiovascular risk by using a novel framework that requires passing prespecified validity checks before analyzing the primary outcome. RESEARCH DESIGN AND METHODS: Within Medicare and two commercial claims data sets (May 2011–September 2015), we identified a 1:1 propensity score–matched (PSM) cohort of T2D patients 40–85 years old at increased cardiovascular risk who initiated linagliptin or glimepiride by adapting eligibility criteria from CAROLINA. PSM was used to balance >120 confounders. Validity checks included the evaluation of expected power, covariate balance, and two control outcomes for which we expected a positive association and a null finding. We registered the protocol (NCT03648424, ClinicalTrials.gov) before evaluating the composite cardiovascular outcome based on CAROLINA’s primary end point. Hazard ratios (HR) and 95% CIs were estimated in each data source and pooled with a fixed-effects meta-analysis. RESULTS: We identified 24,131 PSM pairs of linagliptin and glimepiride initiators with sufficient power for noninferiority (>98%). Exposure groups achieved excellent covariate balance, including key laboratory results, and expected associations between glimepiride and hypoglycemia (HR 2.38 [95% CI 1.79–3.13]) and between linagliptin and end-stage renal disease (HR 1.08 [0.66–1.79]) were replicated. Linagliptin was associated with a 9% decreased risk in the composite cardiovascular outcome with a CI including the null (HR 0.91 [0.79–1.05]), in line with noninferiority. CONCLUSIONS: In a nonrandomized RWD study, we found that linagliptin has noninferior risk of a composite cardiovascular outcome compared with glimepiride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.004 · Cited by 995
When and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Self-citationMarx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212 · cited 2×
“3, as specified in CAROLINA (9) and mandated by the FDA for cardiovascular outcome trials evaluating new therapies for T2D (12).”
BackgroundAzoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195 · cited 1×
“Given that medications of both classes are frequently used as second-line therapy after metformin, and because sulfonylureas have been associated with concerns regarding their cardiovascular safety (10), the results of this trial could have a significant impact on clinical practice if practitioners conclude there is a…”
Background
Cited by
Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051718 · Cited by 299
Self-citationFralick, M., Kim, S. C., Schneeweiss, S., Everett, B. M., Glynn, R. J., & Patorno, E. (2020) · BMJ · doi:10.1136/bmj.m2812 · Cited by 63
Self-citationDesai, R. J., Varma, V. R., Gerhard, T., Segal, J., Mahesri, M., Chin, K., Horton, D. B., Kim, S. C., Schneeweiss, S., & Thambisetty, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6567 · Cited by 45
Self-citationSuissa, K., Schneeweiss, S., Kim, D. W., & Patorno, E. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14367 · Cited by 41
“2), which has been scientifically validated by repeating previously published studies(11) and replicating(12) or predicting clinical trial findings.(13)”
Self-citationDesai, R. J., Levin, R., Lin, K. J., & Patorno, E. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016906 · Cited by 29
Self-citation
Metadata
- Authors
- Patorno, E., Schneeweiss, S., Gopalakrishnan, C., Martin, D., & Franklin, J. M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-07-11
- Volume
- 42
- Issue
- 12
- Pages
- 2204-2210
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2955605212
- Cited by
- 94
- References
- 5
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.